

DIV. OF LAW

Fax:1-973-648-7156

Oct 8 '99 12:43

P.03

JOHN J. FARMER, JR.
ATTORNEY GENERAL OF NEW JERSEY
Division of Law, 5th Floor
124 Halsey Street
P.O. Box 45029
Newark, New Jersey

FILED

October 13, 1999

NEW JERSEY STATE BOARD
OF MEDICAL EXAMINERS

By: Douglas J. Harper
Deputy Attorney General
(973) 648-7457

STATE OF NEW JERSEY
DEPARTMENT OF LAW & PUBLIC SAFETY
DIVISION OF CONSUMER AFFAIRS
BOARD OF MEDICAL EXAMINERS

IN THE MATTER OF THE
SUSPENSION OR REVOCATION OF
THE LICENSE OF

Administrative Action

LANCE L. GOBERMAN, M.D.
LICENSE NO. MA-038191

and

INTERIM CONSENT ORDER

DAVID BRADWAY, M.D.
LICENSE NO. MA-034479

TO PRACTICE MEDICINE AND
SURGERY IN THE STATE OF
NEW JERSEY

This matter having been opened to the Board on the Attorney General's complaint alleging, among other things, that respondents provide a procedure commonly known as UROD or ROD (Ultra Rapid Opiate Detoxification or Rapid Opiate Detoxification) wherein anesthetic agents and opiate antagonists are administered to opiate addicted patients in order to block the effects of opiates, and said complaint further alleging that six deaths and multiple hospitalizations occurred in patients who received UROD/ROD through respondents such that continued provision of the procedure

CERTIFIED TRUE COPY

constitutes a danger to the public's health, safety and welfare, and it appearing that the parties have conferred and that respondents consent to the entry hereof without admission of any factual or legal allegation set forth in said complaint and without prejudice to any rights or positions to be hereafter advanced, and it further appearing that good cause exists for the entry hereof,

IT IS on this 13th day October, 1999

ORDERED:

1. Respondents, either directly or indirectly through any agent, employee or by any other means, shall not offer or provide the UROD/ROD procedure. For the purpose of this order said procedure shall mean the administration of any substance, including any opiate antagonist, to any patient where said patient is under the effect of any anesthetic drug or substance where the purpose of such procedure is to detoxify such patient from the effects of any opiate or any other substance. Nothing herein contained shall prohibit respondents from subcutaneously inserting any naltrexone pellet where said insertion is performed with a local anesthetic agent, provided that the patient is informed in writing that such procedure is not approved as safe and effective by the Food and Drug Administration. Said procedure shall not be performed where the patient's state of consciousness is in anyway altered by any anesthetic agent. Respondents shall immediately notify the Board in writing in the event of any mortality or morbidity known to respondents where such morbidity or mortality occurs within sixty

days following respondents' insertion of a naltrexone pellet. The within provisions shall continue until further order of the Board.


2. In the event that respondents seek to perform UROD/ROD in any hospital or any other in-patient setting within the State of New Jersey, notice of said intention shall be provided to the Board along with a full disclosure of the location at which the procedure is to be performed, the physicians and/or certified registered nurse anesthetists who shall perform and monitor the same, any intended period of hospitalization, and a detailed statement outlining follow-up aftercare as intended. Respondent shall not perform such procedure unless and until written approval thereof is obtained from the Board. Said approval shall be timely provided. In the event approval is withheld or denied reasons for such action shall be set forth in writing.

3. Respondents shall not advertise the availability of UROD/ROD in any medium and shall remove such advertising thereof as may be currently circulating within public media, including but not limited to any billboard advertising, at the earliest possible time. Pending further order of the Board, nothing herein contained shall prohibit respondents from advertising the availability of the naltrexone pellet as an integral part of addiction treatment.

4. Respondents shall appear before a Board committee for the purpose of providing data, research and information as may be necessary for the Board to evaluate respondents' practice regarding naltraxone pellet insertion.

5. Respondents shall, not later than ten days following entry hereof, provide the Board with a full statement of those medical services and procedures which they intend to provide to the public pending final adjudication on the Attorney General's complaint.

6. Nothing herein contained shall limit or prohibit the Board or respondents from taking such action as may otherwise be authorized by law.


 Gregory J. Rokosz, D.O., J.D.
 PRESIDENT,
 State Board of Medical Examiners

I have read and I understand the above stated terms and conditions within this order. I agree to be bound by them, and I hereby give my consent to the Board for the entry of this order.



 Lance L. Gooberman, M.D.


 David Bradway, M.D.

Consented as to form and entry
 Plaster, Greenberg
 Counsel for Respondents

By: 
 Alma L. Saravia, Esq.

JOHN J. FARMER, JR.,
 ATTORNEY GENERAL OF NEW JERSEY
 Counsel for State Board of Medical Examiners

By: 
 Douglas J. Harper
 Deputy Attorney General